HeyJaredJAMA Dermatol
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 24, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Aug 26, 2026
Latest articles
Ruxolitinib Cream Improves Lesions, Itch in Lichen Planus (opens the original)
Read excerpt
A topical Janus kinase (JAK) inhibitor, ruxolitinib, 1.5%, cream was associated with greater improvement in skin lesions and itch than vehicle cream in adults with cutaneous lichen planus (LP), with Investigator’s Global Assessment (IGA) treatment success maintained through week 32. "In this randomized clinical trial of treatment with a topical JAK inhibitor in cutaneous LP, use of ruxolitinib, 1.5%, cream twice daily significantly reduced clinical signs (lesions) of LP and itch," the authors wr
Do IL-17 Inhibitors Increase IBD Risk in HS? (opens the original)
Read excerpt
A meta-analysis found that interleukin-17 (IL-17) inhibitors were not associated with a significantly increased risk for new-onset inflammatory bowel disease (IBD) in patients with hidradenitis suppurativa (HS) compared with placebo, though nonrandomized studies showed higher event rates. "In this systematic review and meta-analysis, IBD events observed during IL-17 inhibitor therapy for HS were rare in clinical trials as well as nonrandomized studies," the authors wrote. "Although the absolute
Vulvar Lichen Sclerosus Affects 1 in 700 US Women (opens the original)
Read excerpt
Vulvar lichen sclerosus (VLS) affected approximately 1.4 per 1000 US women, with prevalence increasing steadily with age and peaking at 3 per 1000 among women aged 70 years or older. White women, particularly those in older age groups, had the highest disease rates. "Nearly 200,000 women in the US may have VLS, a potentially debilitating disease with considerable life impact," the authors wrote. "Quantification of disease burden overall and by subgroups may support early recognition and symptom
Brepocitinib Controls Skin Disease in Dermatomyositis (opens the original)
Read excerpt
Oral brepocitinib, a first-in-class oral, selective tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, improved cutaneous disease activity, pruritus, and skin-related quality of life (QOL) through 52 weeks in adults with dermatomyositis in the prespecified secondary analysis of a phase 3 trial. These results support 30 mg brepocitinib "as a targeted therapy capable of delivering rapid, remission-level control of skin disease in patients with dermatomyositis with a safety profile consi
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.